PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1549
- Registration Number
- NCT00649090
- Locations
- 🇧🇪
Pfizer Investigational Site, Yvoir, Belgium
A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 154
- Registration Number
- NCT00649415
- Locations
- 🇧🇷
Pfizer Investigational Site, São Paulo, Brazil
A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis
Phase 3
Completed
- Conditions
- Bronchitis, Chronic
- Interventions
- Drug: Amoxicillin/clavulinic acidDrug: Azithromycin
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00649831
- Locations
- 🇫🇷
Pfizer Investigational Site, Yerres, France
A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 130
- Registration Number
- NCT00648258
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 248
- Registration Number
- NCT00649311
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 488
- Registration Number
- NCT00650039
- Locations
- 🇨🇦
Pfizer Investigational Site, Weston, Ontario, Canada
A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 197
- Registration Number
- NCT00647829
- Locations
- 🇺🇸
Pfizer Investigational Site, Boca Raton, Florida, United States
Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT00649610
- Locations
- 🇻🇪
Pfizer Investigational Site, Caracas, Venezuela
Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 458
- Registration Number
- NCT00648141
- Locations
- 🇩🇪
Pfizer Investigational Site, Winsen/Luhe, Germany
An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia
Phase 3
Completed
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 139
- Registration Number
- NCT00648726
- Locations
- 🇨🇳
Pfizer Investigational Site, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath